PAN-90806 is under clinical development by PanOptica and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PAN-90806’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PAN-90806 is under development for the treatment of diabetic macular edema, wet AMD, neovascular age-related macular degeneration (neovascular AMD). It is formulated as suspension and administered as ophthalmic drops. The drug candidate selectively targets VEGF receptor. It was under development for the treatment of proliferative diabetic retinopathy as a solution formulation.
PanOptica is a clinical-stage biopharmaceutical company that develops topical eye drops for the treatment of sight-threatening eye diseases. The company concentrates on candidates that are at or near the investigational new drug application stage. It develops PAN-90806, a novel, topically applied, once daily eye drop for the treatment of wet AMD and other neovascular eye diseases. PanOptica’s drugs are used in sight-threatening eye diseases caused by abnormal or leaky blood vessels. The company also partners biopharmaceutical companies to complete development, regulatory approval, and commercialization of the compound. PanOptica is headquartered in Bernardsville, New Jersey, the US.
For a complete picture of PAN-90806’s drug-specific PTSR and LoA scores, buy the report here.